Noelia Nebot - Concepedia

Author

Noelia Nebot

Research Triangle Park Foundation ORCID

Also Known As

N. Nebot, Noelia Nebot

Publications

711

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation Institut Gustave Roussy University College London GlaxoSmithKline (United States)Sarah Cannon Research Institute

About

Noelia Nebot is an author at Research Triangle Park Foundation specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	275
2	Cell Biology	2	2	154
3	Health Sciences	1	1	18
4	Microbiology	1	1	14
5	Neurology	1	1	18

Noelia Nebot

Publications

694

Citations

H-Index

Page 1

	Year	Citations
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors Jean‐Charles Soria, Hui Gan, Sarah P. Blagden, Annals of Oncology Pharmacodynamic StudyMedicineCell AdhesionReceptor Tyrosine KinasePharmacology	2016	140
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours Gabriel Mak, Jean‐Charles Soria, Sarah P. Blagden, British Journal of Cancer	2019	99
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid Tumors Mark W. Kieran, Birgit Geoerger, Ira J. Dunkel, Clinical Cancer Research	2019	91
Participation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes Noelia Nebot, Séverine Crettol, Fabrizio D’Esposito, British Journal of Pharmacology	2010	87
Sorafenib Hepatobiliary Disposition: Mechanisms of Hepatic Uptake and Disposition of Generated Metabolites Brandon Swift, Noelia Nebot, Jin Kyung Lee, Drug Metabolism and Disposition	2013	58
Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation David A. Bershas, Danièle Ouellet, Donna Mamaril-Fishman, Drug Metabolism and Disposition	2013	45
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors Danièle Ouellet, Kenneth F. Grossmann, Giselle Limentani, Journal of Pharmaceutical Sciences OncologyOncogenic AgentMedicineBraf InhibitorPharmacotherapy	2013	44
Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN). Birgit Geoerger, Christopher L. Moertel, James A. Whitlock, Journal of Clinical Oncology Neuro-oncologyTumor BiologyBraf Wt CellsMedicineMitogen-activated Protein Kinase	2018	26
CNS tumours The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas Mark W. Kieran, Éric Bouffet, Uri Tabori, Annals of Oncology Neuro-oncologyRefractory Low-grade GliomasTumoral PathologyPediatric Brain TumorsGlioma	2016	19
Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with <i>BRAF</i> V600–mutant relapsed refractory low-grade glioma. Mark W. Kieran, Éric Bouffet, Alberto Broniscer, Journal of Clinical Oncology Pediatric Brain TumorsPediatric PtsHigh-grade GliomasGliomaNeuro-oncology	2018	18

Page 1